首页> 外文OA文献 >Detection of enzyme activity in orthotopic murine breast cancer by fluorescence lifetime imaging using a fluorescence resonance energy transfer–based molecular probe
【2h】

Detection of enzyme activity in orthotopic murine breast cancer by fluorescence lifetime imaging using a fluorescence resonance energy transfer–based molecular probe

机译:使用基于荧光共振能量转移的分子探针通过荧光寿命成像检测原位鼠乳腺癌中的酶活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cancer-related enzyme activity can be detected noninvasively using activatable fluorescent molecular probes. In contrast to “always-on” fluorescent molecular probes, activatable probes are relatively nonfluorescent at the time of administration due to intramolecular fluorescence resonance energy transfer (FRET). Enzyme-mediated hydrolysis of peptide linkers results in reduced FRET and increase of fluorescence yield. Separation of signal from active and inactive probe can be difficult with conventional intensity-based fluorescence imaging. Fluorescence lifetime (FLT) measurement is an alternative method to detect changes in FRET. Thus, we investigate FLT imaging for in vivo detection of FRET-based molecular probe activation in an orthotopic breast cancer model. Indeed, the measured FLT of the enzyme-activatable molecular probe increases from 0.62 ns just after injection to 0.78 ns in tumor tissue after 4 h. A significant increase in FLT is not observed for an always-on targeted molecular probe with the same fluorescent reporter. These results show that FLT contrast is a powerful addition to preclinical imaging because it can report molecular activity in vivo due to changes in FRET. Fluorescence lifetime imaging exploits unique characteristics of fluorescent molecular probes that can be further translated into clinical applications, including noninvasive detection of cancer-related enzyme activity.
机译:癌症相关的酶活性可以使用可激活的荧光分子探针进行无创检测。与“始终在线”荧光分子探针相反,由于分子内荧光共振能量转移(FRET),可激活探针在给药时相对无荧光。酶介导的肽接头水解会降低FRET,并提高荧光产量。使用常规的基于强度的荧光成像可能很难将信号与活动探针和非活动探针区分开。荧光寿命(FLT)测量是检测FRET变化的另一种方法。因此,我们调查原位乳腺癌模型中体内检测基于FRET的分子探针激活的FLT成像。实际上,酶激活分子探针的测量FLT从刚注射后的0.62 ns增加到4小时后肿瘤组织中的0.78 ns。对于具有相同荧光报告分子的始终在线的靶向分子探针,未观察到FLT的显着增加。这些结果表明,FLT造影剂是临床前成像的有力补充,因为由于FRET的变化,它可以报告体内的分子活性。荧光寿命成像利用了荧光分子探针的独特特征,可以将其进一步转化为临床应用,包括无创检测癌症相关酶的活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号